GSK-49653/461

Study Sponsor: GSK

Study Title

A double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilization and cognition in subjects with mild to moderate Alzheimer's Disease (AD)

Medicine or Vaccine (generic name)

rosiglitazone

Sponsor Identification Number

49653/461

Trial Registry Identification Number(#'s)

NCT00265148 2005-005089-34

Medical Condition

Alzheimer's Disease

Phase

Phase 2

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=BRL-49653/461

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00265148

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005089-34

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

A follow-on study AVA104617 was conducted. An analysis-ready dataset is not available for this study.

Date Added to this Site

September 2013